Lonafarnib，又称洛那法尼，是合成的有抗肿瘤特性的三环羧基酰胺衍生物，是可口服的farnesyltransferase (FTase)抑制剂，能够阻断早衰蛋白的法尼基化，作用于H-Ras/K-Ras/N-Ras，IC₅₀分别为1.9 nM、5.2 nM和2.8 nM。临床上，Lonafarnib适用于治疗早年衰老综合征。

参考文献

[1] Liu M, Bryant MS, Chen J, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998 Nov 1;58(21):4947-56(IF:8.378).

[2] Chun KH, Chun KH, Hassan K, et al. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 2003 Aug 15;63(16):4796-800(IF:8.378).

[3] Feldkamp MM, Lau N, Roncari L, et al. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 2001 Jun 1;61(11):4425-31(IF:8.378).

-25~-15℃保存，有效期3年。